LifeMD investors urged to seek lead plaintiff role by Oct 27, 2025 deadline.

Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. after a federal securities class action was filed against the company. Investors who suffered losses exceeding $75,000 between May 7, 2025 and August 5, 2025 are encouraged to contact James (Josh) Wilson directly to discuss their options. The deadline to seek the role of lead plaintiff is October 27, 2025.

Faruqi & Faruqi, LLP, a leading national securities law firm, has announced an investigation into potential claims against LifeMD, Inc. (NASDAQ: LFMD) following a federal securities class action filed against the company. Investors who suffered losses exceeding $75,000 between May 7, 2025, and August 5, 2025, are encouraged to contact James (Josh) Wilson directly to discuss their options. The deadline to seek the role of lead plaintiff is October 27, 2025.

The complaint alleges that LifeMD and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that:

1. Defendants materially overstated LifeMD’s competitive position.
2. Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound.
3. As a result, Defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On August 5, 2025, after the market closed, LifeMD reported its financial results for the second quarter of 2025. In this announcement, LifeMD stated that it was expecting total revenue in the range of $250 to $255 million, compared with previous guidance of $268 to $275 million. This revision led to a 44.8% plunge in LifeMD's stock on August 6, 2025.

Investors who wish to serve as lead plaintiff must move the Court no later than October 27, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP encourages anyone with information regarding LifeMD’s conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

For more information, visit www.faruqilaw.com/LFMD or contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

References:
[1] https://www.businesswire.com/news/home/20250827078693/en/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-LifeMD